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1. Introduction 
Glaucoma is the second leading cause of blindness in the general population. The definition of 
end-stage glaucoma may be based on a very constricted visual field, or a markedly severed 
visual acuity (Gillies& Brooks et al., 2000). Many factors have been postulated to put the 
patient at a high risk. Achieving an individually fashioned target IOP is supposed to minimize 
the risk of glaucoma progression (Nouri-Mahdavi & Hoffman et al., 2004). Medical regimens 
may induce significant short and long term IOP fluctuations. Surgery should be considered in 
end stage glaucoma. Trabeculectomy has been reported to be associated with less diurnal IOP 
fluctuation compared to maximum medical therapy. Wipe-out phenomenon is a rare 
complication and may be considered as a blast from the past. Meanwhile, Trabeculectomy has 
many surgical difficulties. Emphasis on guidelines for a successful trabeculectomy without toil 
is presented, besides the new modalities to achieve a favorable outcome. 
2. What is end stage glaucoma? 
There is no universally accepted definition of end-stage glaucoma. It may be based on a very 
constricted visual field, less than 10 or a visual acuity of 20/200 or worse that is attributable 
to glaucoma (Gillies & Brooks et al., 2000). 
2.1 Importance 
Glaucoma is the second leading cause of irreversible blindness in the general population, 
and the leading cause of blindness in black patients. Besides, patients with end-stage 
glaucoma have a high risk of further disease progression. Although peripheral vision is 
seriously affected, these patients may maintain good central vision sufficient enough to 
perform simple daily tasks. 
2.2 Diagnostic challenge 
End stage glaucoma carries a diagnostic challenge. Visual field examination is either 
unreliable or impossible. Only when a central island of vision remains, visual field tests of 
the central degrees should be chosen. Small changes in the visual field may be deleterious to 
central vision but it can be difficult to differentiate them from inter-test fluctuation. Small 
neuroretinal rim changes may correspond to significant changes in the visual acuity. On the 
other hand, OCT may be useful in the detection of glaucomatous progression. In advanced 
or progressive glaucoma, imaging can be justified every 3–4 months to look for change 
(Bartz-Schmidt & Thumann G et al., 1999). 
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2.3 Risk factors for progression 
Many factors have been proved to increase the risk of glaucoma progression in end stage 
glaucoma, The most important are elevated intraocular pressure (IOP), IOP fluctuations, 
male gender, less formal education, severity of disease, pseudoexfoliation syndrome, 
worsening visual fields during follow up, optic disc hemorrhage, advanced stage of disease, 
migraine, patient’s expected longevity, and the possibility of systemic diseases e.g 
hypertension, diabetes, and myopia (Law & Nguyen et al., 2007). 
3. Target IOP in end stage glaucoma 
Target IOP is the IOP that minimizes the risk of glaucoma progression with minimum 
impact on the quality of life. Although the concept of a target IOP is debated, it is 
recommended that every patient should have an individualized target IOP and re-estimated 
according to the follow up. Target IOP may be a percent reduction from a baseline IOP or 
may be an absolute IOP reduction. It is generally assumed that aiming to achieve a target 
IOP of at least a 20% reduction from the initial pressure at which damage occurred is a 
useful starting point. For moderate and advanced damage, a 30 and 40% decrease of IOP 
from baseline, respectively, is proposed. In each individual, the efficacy of any treatment 
lowering the IOP less than 15% should be questioned. The range of IOP fluctuations should 
also be considered and when in doubt a diurnal curve is indicated. Besides, the greater the 
pre-existing glaucoma damage, the lower the target IOP should be. It is clinically relevant 
that in eyes with severe pre-existing damage, any further damage may be functionally 
important. Thus, IOP should be set low in end-stage glaucoma. Target pressures seem to 
drop to lower and lower levels each decade. Even a more lower target IOP may be needed if 
other risk factors are present specially diabetes mellitus and hypertension. Severe 
pre-existing damage in the fellow eye is another possible risk factor, as well as a positive 
family history of visual handicap caused by primary open-angle glaucoma (POAG). A 
further 3% IOP lowering for each risk factor or for each decade of life expectancy is advised. 
Periodical re-evaluation and adjustments are necessary if the visual field continues to 
worsen at a rate that is clinically significant, it may be necessary to aim for a lower target 
IOP after other causes have been excluded (Miglior & Bertuzzi , 2010).. 
3.1 Medical versus interventional strategy 
The target IOP may not be achieved despite maximum medical therapy. Even if end stage 
glaucoma could be controlled medically, the lack of adherence and persistence with 
medication regimens may induce significant short and long term IOP fluctuations. These 
fluctuations have a deleterious effect on the visual outcomes. Medication may be 
inappropriate in some clinical situations. Extremely high IOP may be unlikely to be 
sufficiently reduced by medications. In this case medical treatment may be initiated briefly 
in order to operate at lower IOP.Some patients may have secondary conditions that interfere 
with the ability to administer medication such as dementia, mental illness, or 
arthritis.Economic problems are also challenges for patients in many locations. This may 
limit or effectively exclude access to medical treatment for glaucoma. Limited access to 
medical resources may be based on other factors such as distance from medical care and 
limited availability of practitioners and medications.On the other hand, glaucoma 
procedures are associated with more tight IOP control and minimal IOP fluctuations. There 
is a growing evidence that glaucoma procedures are more helpful in prevention of visual 
field loss when further IOP reduction is needed despite maximum medical therapy. There 
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are no clearly defined and accepted rules to decide when surgery is the appropriate 
therapeutic choice, but there are principles that seem to guide this decision. Several 
assumptions underlie the recommendation of surgery for the treatment of glaucoma. 
Among these are the observation that surgical IOP lowering stops or slows progressive 
glaucoma damage. Even more, greater IOP lowering can be achieved with surgery than with 
medication in many patients, while surgery has greater risk than medical treatment of 
glaucoma. Intra-operative risks such as suprachoroidal haemorrhage, and post-operative 
risks such as hypotony and bleb related infection can result in rapid and profound visual 
loss.For example, trabeculectomy has been reported to be associated with less diurnal IOP 
fluctuation compared with maximum medical therapy in patients with end stage glaucoma . 
On the contrary, if the central fixation has already been lost, glaucoma procedures add no 
more beneficial effect and it is suggested to consider withholding surgery. 
4. Surgical intervention in end stage glaucoma 
4.1 Surgical options of end stage glaucoma 
The surgical options for end stage glaucoma are generally the same as those of earlier stages 
of glaucoma. Many trabeculectomy modalities are suitable for end stage glaucoma. While 
trabeculectomy is the treatment of choice in primary open angle glaucoma, consider lens 
removal (combined surgery) in patients with end-stage chronic angle closure glaucoma. 
This offers the best chance to deepen the anterior chamber and widen the angle. 
Trabeculectomy with antimetabolites reduces IOP more compared with trabeculectomy 
alone. Ologen collagen matrix is a new promising modality that carries a superior advantage 
over conventional trabeculectomies and antimetabolites. Glaucoma drainage implants are 
indicated after glaucoma filtration surgery failure, on the other hand cycloablation in the 
form of cyclophotocoagulation or cyclocryotherapy are indicated for eyes with poor vision.  
4.2 Preoperative preparation 
A proper preoperative preparation is essential for a successful glaucoma surgery outcome.  
Adequate management of blood pressure, coagulation profile by the physician is crucial 
.Preoperative Visual field is important for medical and medico-legal reasons. Topical 
corticosteroids such as fluoromethelone may be used to calm down any claimed 
inflammation. Glaucoma lowering agents should be stopped several days in advance.  
4.3 Anaesthetic precautions 
Ophthalmic anaesthesia planning is of great help in end stage glaucoma surgery. General 
anaethesia is considered for one-eyed patients as possible. Certain precautions are 
mandatory during local anesthesia particularly reduction of the volume, addition of 
hyaluronidase and avoidance of orbital compression. Facial block is important to produce 
enough facial akinesia. Subtenon or peribulbar anaethesia do worth consideration 
particularly for myopia. 
4.4 Difficulties of surgical intervention in end stage glaucoma 
It has been well noticed that procedures in end stage glaucoma carries more surgical 
difficulties. This is because of the possibility of previous operations (glaucoma or cataract) 
and the long term use of topical glaucoma drugs. These co-morbidities have negative effects 
on the conjunctiva, and on the outcome of a new operation. 
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5. Conventional trabeculectomy in end stage glaucoma 
Trabeculectomy should be fashioned properly and with extreme caution in end stage 
glaucoma to achieve the best favorable outcomes. Fornix-based flaps are preferred for better 
exposure of the sclera and less chance of a posterior scar formation. A corneal traction 
suture is suggested to avoid formation of a superior rectus haematoma.An anterior segment 
infusion system through the paracentesis is helpful in stabilizing the IOP during surgery, 
decrease the risk of serious complications, and enable more accurate suturing of the scleral 
flap. Bleb is fashioned under the upper lid to minimize discomfort and bleb-related 
complications, such as leak or infection. The scleral flap must be sufficiently large and of 
adequate thickness to provide resistance to aqueous outflow, especially if antimetabolites 
are used. Besides, the side incisions are left incomplete (1–2 mm from limbus) to encourage 
posterior flow and achieve a diffuse bleb. Scleral flap sutures can be pre-placed while the 
eye is still firm. Adjustment of sutures of the scleral flap should be based on intraoperative 
evaluation of flow. 
 
 
Fig. 1. (RT) Fornix-based flaps for better exposure of the sclera and less chances of a 
posterior scar. A corneal traction suture avoids the formation of a superior rectus 
haematoma, (LT) The scleral flap must be sufficiently large and of adequate thickness to 
provide resistance to aqueous outflow. (Fellman, 2009) 
Many modalities of scleral flap sutures are of great help. Among those are fixed interrupted 
sutures that can be lasered later, releasable sutures that can be pulled out postoperatively 
and adjustable sutures that can be loosened transconjunctivally. Meticulous conjunctival 
closure is a priority to avoid hazardous postoperative bleb leakage and hypotony. Careful 
postoperative IOP measurement is indicated to detect early IOP spikes which could result in 
optic nerve damage. Bleb leakage and signs of inflammation should always be examined. 
6. Trabeculectomy with antimetabolites 
Tissue healing can be modulated with antimetabolites to improve outcomes of 
trabeculectomy. Antimetabolites are not very often used for the first trabeculectomies, but 
are mandatory after previous trabeculectomy or cataract surgery and for combined cataract–
trabeculectomy surgery. Also they are indicated with trabeculectomy failure in the other eye 
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and for dark skin and young patients. Antimetabolites are applied with a low dose, short 
duration, and on the largest possible area. While preoperative subconjunctival mitomycin-C 
(MMC) has less cytotoxic effect on the ciliary body compared with intraoperative episcleral 
application, both preoperative and intraoperative applications of MMC are effective in 
controlling IOP with a safer course and less postoperative complications in preoperative 
subconjunctival injection. Argon laser trabeculoplasty as an adjuvant therapy before or after 
trabeculectomy is an issue of controverse. Black and white patients with advanced glaucoma 
respond differently. Blacks with end stage glaucoma benefit more from a regimen that 
begins with laser surgery, and whites benefit more from one that begins with 
trabeculectomy. 
7. Glaucoma filtering surgery with amniotic membrane transplantation 
7.1 Principle 
Antimetabolites may influence the integrity of the conjunctival barrier, resulting in a thin-
walled avascular bleb (Hutchinson & Grossniklaus et al., 1997). The end result is often poor 
epithelialization and increased susceptibility to leakage and hypotony or infection, 
sometimes months after surgery (Parrish & Minckler, 1996). On the other hand, amniotic 
membrane exhibits a number of characteristics that might be of benefit in glaucoma surgery, 
that is good epithelization, good integration with the surrounding tissue, a low healing 
response, suppression of TGF-B activity and poor immunogenicity (Willoch & Nicolaissen, 
2003). These features of amniotic membrane make it an attractive tissue for use in glaucoma 
surgery. It has been used in filtration surgery as an adjunct to reduce scarring, for repair of 
leaking blebs and as a cover for valve implant (Fujishima & Shimazaki et al., 1998). 
7.2 Operative technique 
 
 
Fig. 2. (A) Peeling of aminiotic membrane from Nitro celluose paper, (B) Amniotic 
membrane graft is placed under the scleral flap and suturing of the graft to the sclera, (C) 
Trabeculectomy measuring 2X3 mm is done (D) Second graft over the scleral flap ( Mokbel 
& El-hefny et al., 2005) 
C D
A B
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Fornix based conjunctival flap, care was taken to ensure haemostasis during the whole 
surgical procedure. Scleral flap was done measuring 4x5 mm. Previously prepared amniotic 
membrane which is preserved in Dulbeccos Modified Eagles Media (DME) at -80ºC and was 
known to be free from HIV, HCV, HBV and syphilis was used Fig. 2(A). Amniotic 
membrane graft measuring 3x8 mm with its epithelial side up was placed between the 
scleral flap and deep sclera and attached to the scleral with four 10-0 nylon sutures at the 
corners Fig. 2(B). The amniotic membrane was then retracted and trabeculectomy measuring 
2x3 mm was done Fig. 2(C). The scleral flap was then closed by two 10/0 nylon sutures. A 
second graft of amniotic membrane measuring 1.5x1.5 cm was placed over the sclera and 
attached near the limbus by two 10-0 nylon sutures and posteriorly by other two sutures 
Fig. 2(D). The conjunctiva was then closed using two 8/0 virgin sutures at the corners. 
Postoperatively each patient recieved a subconjunctival injection of Dexamethazone and 
garamycin followed by topical application of 5 times daily tobramycin & Dexamethazone 
drops for 4 weeks. All antiglaucoma medications were stopped ( Mokbel & El-hefny et al., 
2005). 
8. Ologen collagen matrix 
Ologen is porcine extracellular matrix made of atelocollagen cross-linked with 
glycosaminoglycan. Ologen is a biodegradable scaffolding matrix that induces a 
regenerative wound healing process without the need for antifibrotic agents. It is well 
known that episcleral fibrosis and sub-conjunctival scarring are the major causes of failure 
in glaucoma filtering surgery. Ologen collagen matrix can creat the sub-conjunctival bleb 
and modulate the wound healing for the surgery. Ologen collagen matrix is a 3-D scaffold 
porous structure that can guide fibroblast to grow randomly, instead of linear alignment. 
This can reduce sub-conjuctival and trabdoor scars. Thus, Ologen collagen matrix carries the 
 
 
Fig. 3. Ologen implant,diffuse bleb and a well formed anterior chamber (photo of the 
author) 
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advantage of lowering IOP more safely and efficiently than standard trabeculectomy with 
MMC, with the merit of less possibility of bleb leaks and endophthalmitis compared with 
antimetabolites (Sarkisian, 2010).  
The collagen matrix helps to limit hypotony through a tamponading effect over the scleral 
flap. On the other hand Ologen collagen matrix carry the disadvantage of increased cost, 
besides the difficulty of laser suture lysis. 
8.1 Technique  
According to the surgeon preference, limbal - or a fornix-based conjunctival flap are 
accepted. A loose stitch sclera flap is done in order to encourage aqueous flow for the 
filtering surgery. Ologen collagen matrix disc is implanted over the scleral flap. No suture is 
required to secure the implant, and as soon as it touches the sclera, it absorbs aqueous and 
molds to cover the scleral tissue. Collagen matrix therefore need not be presoaked or 
prepared in any way. After the collagen matrix’s placement, the surgeon closes the 
conjunctiva in his or her usual meticulous fashion to ensure that the wound is watertight.  
 
 
Fig. 4. Ologen implant, next day after surgery (photo of the author) 
Ologen currently comes in two sizes for glaucoma filtering surgery: 6 X 2 mm and 12 X 1 
mm. The numbers 6 and 12 stands for the diameter of the round implant, and the numbers 2 
and 1 refer to its thickness. Ologen is biodegradable in 90 to 180 days. Ologen has been 
approved by the FDA in August 2009 (Sarkisian, 2010). 
9. Aqueous shunting procedures with glaucoma drainage devices 
Glaucoma drainage devices (GGDs) are indicated when trabeculectomy is unlikely to be 
successful. Besides, GDDs should be considered for socioeconomic or logistical issues 
relating to safety, follow-up care, etc. GDDs that do not have mechanisms to restrict 
aqueous flow require a suture ligature or internal stent or other flow restricting mechanism 
because the restriction of flow of aqueous humor from the eye is important in the prevention 
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of postoperative hypotony. There are several type of devices; however, they can be divided 
into two categories:anterior drainage devices and posterior drainage devices. Most posterior 
drainage devices are composed of a silicone or Silastic tube that is placed into the eye 
(through the limbus or pars plana) and through which aqueous humor passes into the 
episcleral-subconjunctival space near the globe’s equator. In this area there is an episcleral 
plate that is designed to maintain an aqueous reservoir. There are three design features 
which distinguish different implants; the presence of a valve or mechanism to restrict the 
flow of aqueous humor from the eye, the surface area and configuration of the episcleral 
plate, and the the material used.Drainage devices without a built in flow restriction 
mechanism, such as the Molteno, Baerveldt, and Schocket band implants, may be inserted in 
a one-stage procedure, where the flow of aqueous is restricted by a suture ligature around 
the tube or an internal stent. On the other hand krupin Valve implant and Ahmed Glaucoma 
Valve implant have pressure-sensitive valves or mechanisms which restrict the flow of 
aqueous from the eye (Mokbel, 2005). 
10. Cyclodestruction 
Cyclodestructive procedures aim to decrease aqueous humor secretion by damaging the 
ciliary processes, thereby reducing intraocular pressure (IOP). Modalities for 
cyclodestruction include cyclocryotherapy, and cyclophotocoagulation, using the Nd:YAG 
or diode laser. Endoscopic, non-contact and contact modes of cyclophotocoagulation are 
available, with the contact diode mode most widely used, laser diode cyclophotocoagulation 
is the procedure of choice for end stage glaucoma when trabeculectomy and drainage 
implants have a high probability for failure or have high risk of surgical complications. Less 
intense laser therapy on a repeated basis rather than a single high dose treatment is 
suggested to minimize complications of treatment. The effectiveness of treatment should be 
assessed after 3-4 weeks, at which time re-treatment may be considered. 
11. Risk of losing vision  
The patient should be informed about the relative risk of losing vision from a surgical 
procedure in end-stage glaucoma eyes. Visually devastating complications include chronic 
hypotony (leading to hypotony maculopathy), retinal detachment, malignant glaucoma, 
corneal decompensation, endophthalmitis, and phthisis bulbi. A detailed clearly written 
patient consent is important.It should entail all the potential hazards from suggested 
surgical procedure.  
11.1 Wipe-out phenomenon 
The wipe-out phenomenon is unexplained vision loss following glaucoma surgery. Wipe-
out phenomenon data comes from older retrospective reports using older surgical 
techniques. Newer data does not report the occurrence of the wipe-out phenomenon. 
12. Conclusion 
In end stage glaucoma there is a higher incidence of visual loss than early glaucoma. So, 
frequent patient monitoring and quick decision making should be done.The target IOP in 
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end stage glaucoma is lower than in early stage. Surgery should be considered in end stage 
glaucoma. Wipe-out phenomenon is a rare complication and may be considered as a blast 
from the past.  
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